Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2017
At a glance
- Drugs AVXS 101 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions
- Sponsors AveXis
- 21 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
- 21 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2018.
- 24 May 2017 Interim results (15Sept16 cut-off) presented at the 113th International Conference of the American Thoracic Society.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History